Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 165

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Angiotensins in Alzheimer's disease – friend or foe?

Kehoe, Patrick G., Miners, Scott, Love, Seth·2009·Trends in Neurosciences
DOI 10.1016/j.tins.2009.07.006
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.tins.2009.07.006

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Research works printed but not linked: 91

  1. Ferri, 2005, Global prevalence of dementia: a Delphi consensus study, Lancet, 366, 2112, 10.1016/S0140-6736(05)67889-0 · DOI · Paper page
  2. Dannenberg, 1988, Incidence of hypertension in the Framingham Study, Am. J. Public Health, 78, 676, 10.2105/AJPH.78.6.676 · DOI · Paper page
  3. Skoog, 2006, Update on hypertension and Alzheimer's disease, Neurol. Res., 28, 605, 10.1179/016164106X130506 · DOI · Paper page
  4. Kehoe, 2003, The renin-angiotensin-aldosterone system and Alzheimer's disease?, J. Renin Angiotensin Aldosterone Syst., 4, 80, 10.3317/jraas.2003.017 · DOI
  5. Papademetriou, 2005, Hypertension and cognitive function. Blood pressure regulation and cognitive function: a review of the literature, Geriatrics, 60, 20
  6. Kalman, 2008, [Recognition and treatment of behavioral and psychological symptoms of dementias: lessons from the CATIE-AD study], Neuropsychopharmacol. Hung., 10, 233
  7. Hardy, 2002, The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics, Science, 297, 353, 10.1126/science.1072994 · DOI · Paper page
  8. Pákáski, 2008, Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease, Neurochem. Int., 53, 103, 10.1016/j.neuint.2008.06.005 · DOI · Paper page
  9. Kehoe, 2008, Vol. 9
  10. Hardy, 1997, Amyloid, the presenilins and Alzheimer's disease, Trends Neurosci., 20, 154, 10.1016/S0166-2236(96)01030-2 · DOI · Paper page
  11. Tyler, 2002, alpha- and beta-secretase: profound changes in Alzheimer's disease, Biochem. Biophys. Res. Commun., 299, 373, 10.1016/S0006-291X(02)02635-9 · DOI · Paper page
  12. Miners, 2008, Aβ-degrading enzymes in Alzheimer's disease, Brain Pathol., 18, 240, 10.1111/j.1750-3639.2008.00132.x · DOI · Paper page
  13. Deane, 2009, Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer's disease, CNS Neurol. Disord. Drug Targets, 8, 16, 10.2174/187152709787601867 · DOI · Paper page
  14. Weller, 2008, Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease, Brain Pathol., 18, 253, 10.1111/j.1750-3639.2008.00133.x · DOI · Paper page
  15. Zlokovic, 2005, Neurovascular mechanisms of Alzheimer's neurodegeneration, Trends Neurosci., 28, 202, 10.1016/j.tins.2005.02.001 · DOI · Paper page
  16. Longo, 1966, Behavioral and electroencephalographic effects of atropine and related compounds, Pharmacol. Rev., 18, 965, 10.1016/S0031-6997(25)07156-X · DOI · Paper page
  17. Saxena, 2009, Lipid metabolism and Alzheimer's disease: pathways and possibilities, Expert Opin. Ther. Targets, 13, 331, 10.1517/14728220902738720 · DOI
  18. Rogers, 2008, The inflammatory response in Alzheimer's disease, J. Periodontol., 79, 1535, 10.1902/jop.2008.080171 · DOI
  19. Kalback, 2004, Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease, Neurol. Res., 26, 525, 10.1179/016164104225017668 · DOI · Paper page
  20. Chiu, 1989, Identification of angiotensin II receptor subtypes, Biochem. Biophys. Res. Commun., 165, 196, 10.1016/0006-291X(89)91054-1 · DOI · Paper page
  21. Whitebread, 1989, Preliminary biochemical characterization of two angiotensin II receptor subtypes, Biochem. Biophys. Res. Commun., 163, 284, 10.1016/0006-291X(89)92133-5 · DOI · Paper page
  22. Marcheselli, 2008, Renin-angiotensin system and stroke, Neurol. Sci., 29, S277, 10.1007/s10072-008-0963-9 · doi:10.1007/s10072-008-0963-9
  23. Fyhrquist, 2008, Renin-angiotensin system revisited, J. Intern. Med., 264, 224, 10.1111/j.1365-2796.2008.01981.x · DOI · Paper page
  24. Haulica, 2005, Angiotensin peptides and their pleiotropic actions, J. Renin Angiotensin Aldosterone Syst., 6, 121, 10.3317/jraas.2005.018 · DOI
  25. Stanton, 2003, Potential of renin inhibition in cardiovascular disease, J. Renin Angiotensin Aldosterone Syst., 4, 6, 10.3317/jraas.2003.008 · DOI
  26. Reaux, 2000, Aminopeptidase A, which generates one of the main effector peptides of the brain renin-angiotensin system, angiotensin III, has a key role in central control of arterial blood pressure, Biochem. Soc. Trans., 28, 435, 10.1042/0300-5127:0280435 · doi:10.1042/0300-5127:0280435
  27. Tabrizchi, 2003, Dual ACE and neutral endopeptidase inhibitors: novel therapy for patients with cardiovascular disorders, Drugs, 63, 2185, 10.2165/00003495-200363200-00003 · DOI
  28. Alison Taylor, 2001, Alzheimer disease is not associated with polymorphisms in the angiotensinogen and renin genes, Neuropsychiatr. Genet., 105, 761, 10.1002/ajmg.10044 · DOI
  29. Danilov, 1996, Development of enzyme-linked immunoassays for human angiotensin I converting enzyme suitable for large-scale studies, J. Hypertens., 14, 719, 10.1097/00004872-199606000-00007 · DOI
  30. Cox, 2002, Angiotensin-1-converting enzyme (ACE) plasma concentration is influenced by multiple ACE-linked quantitative trait nucleotides, Hum. Mol. Genet., 11, 2969, 10.1093/hmg/11.23.2969 · DOI
  31. McKenzie, 2005, SNP haplotypes in the angiotensin I-converting enzyme (ACE) gene: analysis of Nigerian family data using gamete competition models, Ann. Hum. Genet., 69, 227, 10.1046/j.1469-1809.2004.00142.x · doi:10.1046/j.1469-1809.2004.00142.x
  32. Villard, 1996, Identification of new polymorphisms of the angiotensin I-converting enzyme (ACE) gene, and study of their relationship to plasma ACE levels by two-QTL segregation-linkage analysis, Am. J. Hum. Genet., 58, 1268
  33. Elkins, 2004, Alzheimer disease risk and genetic variation in ACE: a meta-analysis, Neurology, 62, 363, 10.1212/01.WNL.0000106823.72493.FF · DOI
  34. Kehoe, 2003, Haplotypes extending across ACE are associated with Alzheimer's disease, Hum. Mol. Genet., 12, 859, 10.1093/hmg/ddg094 · DOI
  35. Narain, 2000, The ACE gene and Alzheimer's disease susceptibility, J. Med. Genet., 37, 695, 10.1136/jmg.37.9.695 · DOI
  36. Ioannidis, 2008, Assessment of cumulative evidence on genetic associations: interim guidelines, Int. J. Epidemiol., 37, 120, 10.1093/ije/dym159 · DOI · Paper page
  37. Kauwe, 2009, Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta, Neurogenetics, 10, 13, 10.1007/s10048-008-0150-4 · DOI · Paper page
  38. Meng, 2006, Association of polymorphisms in the Angiotensin-converting enzyme gene with Alzheimer disease in an Israeli Arab community, Am. J. Hum. Genet., 78, 871, 10.1086/503687 · DOI · Paper page
  39. Schjeide, 2009, Assessment of Alzheimer's disease case-control associations using family-based methods, Neurogenetics, 10, 19, 10.1007/s10048-008-0151-3 · DOI · Paper page
  40. Kehoe, 2004, Common variants of ACE contribute to variable age-at-onset of Alzheimer's disease, Hum. Genet., 114, 478, 10.1007/s00439-004-1093-y · DOI
  41. Sleegers, 2005, ACE gene is associated with Alzheimer's disease and atrophy of hippocampus and amygdala, Neurobiol. Aging, 26, 1153, 10.1016/j.neurobiolaging.2004.09.011 · DOI
  42. Lendon, 2002, The angiotensin 1-converting enzyme insertion (I)/deletion (D) polymorphism does not influence the extent of amyloid or tau pathology in patients with sporadic Alzheimer's disease, Neurosci. Lett., 328, 314, 10.1016/S0304-3940(02)00553-0 · DOI
  43. Miners, 2009, Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes, Am. J. Transl. Res., 1, 163
  44. Carrasquillo, 2009, Genetic variation in PCDH11X is associated with susceptibility to late-onset Alzheimer's disease, Nat. Genet., 41, 192, 10.1038/ng.305 · DOI · Paper page
  45. Thornton-Wells, 2008, Confronting complexity in late-onset Alzheimer disease: application of two-stage analysis approach addressing heterogeneity and epistasis, Genet. Epidemiol., 32, 187, 10.1002/gepi.20294 · DOI
  46. Edwards, 2009, An association analysis of Alzheimer disease candidate genes detects an ancestral risk haplotype clade in ACE and putative multilocus association between ACE, A2M, and LRRTM3, Am. J. Med. Genet. B Neuropsychiatr. Genet., 150B, 721, 10.1002/ajmg.b.30899 · DOI
  47. Lee, 2008, Analyses of the National Institute on Aging Late-Onset Alzheimer's Disease Family Study: implication of additional loci, Arch. Neurol., 65, 1518, 10.1001/archneur.65.11.1518 · DOI
  48. van Esch, 2008, Different contributions of the angiotensin-converting enzyme C-domain and N-domain in subjects with the angiotensin-converting enzyme II and DD genotype, J. Hypertens., 26, 706, 10.1097/HJH.0b013e3282f465d2 · DOI
  49. Arregui, 1982, Angiotensin converting enzyme in Alzheimer's disease increased activity in caudate nucleus and cortical areas, J. Neurochem., 38, 1490, 10.1111/j.1471-4159.1982.tb07930.x · DOI
  50. Barnes, 1991, Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease, Eur. J. Pharmacol., 200, 289, 10.1016/0014-2999(91)90584-D · DOI
  51. Kalaria, 1989, Reduced glucose transporter at the blood-brain barrier and in cerebral cortex in Alzheimer disease, J. Neurochem., 53, 1083, 10.1111/j.1471-4159.1989.tb07399.x · DOI · Paper page
  52. McGeer, 1992, Angiotensin-converting enzyme in cortical tissue in Alzheimer's and some other neurological diseases, Dementia, 3, 299
  53. Savaskan, 2001, Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia, Neurobiol. Aging, 22, 541, 10.1016/S0197-4580(00)00259-1 · DOI · Paper page
  54. Miners, 2008, Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy, Neuropathol. Appl. Neurobiol., 34, 181, 10.1111/j.1365-2990.2007.00885.x · DOI · Paper page
  55. Zubenko, 1986, Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study, Biol. Psychiatry, 21, 1365, 10.1016/0006-3223(86)90328-8 · DOI
  56. Zubenko, 1985, Cerebrospinal fluid levels of angiotensin-converting enzyme in Alzheimer's disease, Parkinson's disease and progressive supranuclear palsy, Brain Res., 328, 215, 10.1016/0006-8993(85)91032-7 · DOI
  57. Konings, 1993, Re-evaluation of cerebrospinal fluid angiotensin-converting enzyme activity in patients with ‘probable’ Alzheimer's disease, Eur. J. Clin. Chem. Clin. Biochem., 31, 495
  58. Nielsen, 2007, Soluble adhesion molecules and angiotensin-converting enzyme in dementia, Neurobiol. Dis., 26, 27, 10.1016/j.nbd.2006.11.011 · DOI · Paper page
  59. Savaskan, 1991, Angiotensin II immunoreactivity in the human striatum and hippocampus of elderly controls and patients with senile dementia of the Alzheimer type and multi-infarct dementia, Dementia, 2, 314
  60. AbdAlla, 2009, Angiotensin II AT2 receptor oligomers mediate G-protein dysfunction in an animal model of Alzheimer disease, J. Biol. Chem, 284, 6554, 10.1074/jbc.M807746200 · DOI
  61. Janciauskiene, 2009, A link between sICAM-1, ACE and parietal blood flow in the aging brain, Neurobiol. Aging, 30, 1504, 10.1016/j.neurobiolaging.2007.08.025 · DOI
  62. Hu, 2001, Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity, J. Biol. Chem., 276, 47863, 10.1074/jbc.M104068200 · DOI · Paper page
  63. Hemming, 2005, Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor, J. Biol. Chem., 280, 37644, 10.1074/jbc.M508460200 · DOI · Paper page
  64. Oba, 2005, The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide, Eur. J. Neurosci, 21, 733, 10.1111/j.1460-9568.2005.03912.x · DOI
  65. Toropygin, 2008, Rapid Commun. Mass Spectrom, 22, 231, 10.1002/rcm.3357 · DOI
  66. Hemming, 2007, Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease, Neurobiol. Dis., 26, 273, 10.1016/j.nbd.2007.01.004 · DOI
  67. Zou, 2007, Angiotensin-converting enzyme converts amyloid beta-protein 1–42 (Abeta(1–42)) to Abeta(1–40), and its inhibition enhances brain Abeta deposition, J. Neurosci., 27, 8628, 10.1523/JNEUROSCI.1549-07.2007 · DOI · Paper page
  68. Hou, 2008, Altered angiotensin-converting enzyme and its effects on the brain in a rat model of Alzheimer disease, Chin. Med. J. (Engl.), 121, 2320, 10.1097/00029330-200811020-00019 · DOI
  69. Wang, 2007, Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease, J. Clin. Invest., 117, 3393, 10.1172/JCI31547 · DOI · Paper page
  70. Mogi, 2008, Telmisartan prevented cognitive decline partly due to PPAR-gamma activation, Biochem. Biophys. Res. Commun., 375, 446, 10.1016/j.bbrc.2008.08.032 · DOI
  71. Santos, 2005, Peroxisomal proliferation protects from beta-amyloid neurodegeneration, J. Biol. Chem., 280, 41057, 10.1074/jbc.M505160200 · DOI
  72. AbdAlla, 2009, Dominant negative AT2 receptor oligomers induce G-protein arrest and symptoms of neurodegeneration, J. Biol. Chem., 284, 6566, 10.1074/jbc.M808277200 · DOI
  73. Sun, 2008, Catabolic attacks of membrane-bound angiotensin-converting enzyme on the N-terminal part of species-specific amyloid-[beta] peptides, Eur. J. Pharmacol., 588, 18, 10.1016/j.ejphar.2008.03.058 · DOI
  74. Barnes, 1992, Angiotensin-converting enzyme inhibition, angiotensin, and cognition, J. Cardiovasc. Pharmacol., 19, S63, 10.1097/00005344-199219006-00011 · DOI
  75. Hamdi, 2004, A genetic variant of ACE increases cell survival: a new paradigm for biology and disease, Biochem. Biophys. Res. Commun., 318, 187, 10.1016/j.bbrc.2004.04.004 · DOI
  76. Suzuki, 2003, Inflammation and angiotensin II, Int. J. Biochem. Cell Biol., 35, 881, 10.1016/S1357-2725(02)00271-6 · DOI · Paper page
  77. Wosik, 2007, Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis, J. Neurosci, 27, 9032, 10.1523/JNEUROSCI.2088-07.2007 · DOI · Paper page
  78. Gard, 2004, Angiotensin and Alzheimer's disease: therapeutic prospects, Expert Rev. Neurother., 4, 87, 10.1586/14737175.4.1.87 · DOI
  79. Chai, 2008, Development of cognitive enhancers based on inhibition of insulin-regulated aminopeptidase, BMC Neurosci., 9, S14, 10.1186/1471-2202-9-S2-S14 · DOI
  80. Forette, 1998, Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial, Lancet, 352, 1347, 10.1016/S0140-6736(98)03086-4 · DOI · Paper page
  81. Tzourio, 2003, Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease, Arch. Intern. Med., 163, 1069, 10.1001/archinte.163.9.1069 · DOI · Paper page
  82. Peters, 2008, Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial, Lancet Neurol., 7, 683, 10.1016/S1474-4422(08)70143-1 · DOI · Paper page
  83. Ohrui, 2004, Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan, J. Am. Geriatr. Soc., 52, 649, 10.1111/j.1532-5415.2004.52178_7.x · DOI
  84. Wolozin, B. et al. (2008) Use of angiotensin receptor blockers is associated with lower incidence and progression of Alzheimer's disease. In Alzheimer's Association International Conference on Alzheimer's Disease (ICAD) July 26–31, 2008 McCormick Place, Chicago, IL, p. T118, Supplement to Alzheimer's & Dementia The Journal of the Alzheimer's Association, Elsevier
  85. Weiner, 1992, ACE inhibitor lacks acute effect on cognition or brain blood flow in Alzheimer's disease, Drug Dev. Res., 26, 467, 10.1002/ddr.430260410 · DOI
  86. Sudilovsky, 1993, A pilot clinical trial of the angiotensin-converting enzyme inhibitor ceranapril in Alzheimer disease, Alzheimer Dis. Assoc. Disord., 7, 105, 10.1097/00002093-199307020-00006 · DOI
  87. Louis, 1999, Use of computerized neuropsychological tests (CANTAB) to assess cognitive effects of antihypertensive drugs in the elderly. Cambridge Neuropsychological Test Automated Battery, J. Hypertens., 17, 1813, 10.1097/00004872-199917121-00005 · DOI
  88. Ohrui, 2004, Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression, Neurology, 63, 1324, 10.1212/01.WNL.0000140705.23869.E9 · DOI · Paper page
  89. Hajjar, 2005, Cross-sectional and longitudinal association between antihypertensive medications and cognitive impairment in an elderly population, J. Gerontol. A Biol. Sci. Med. Sci., 60, 67, 10.1093/gerona/60.1.67 · DOI
  90. He, 2006, ACE activity in CSF of patients with mild cognitive impairment and Alzheimer disease, Neurology, 67, 1309, 10.1212/01.wnl.0000238102.04582.ec · DOI
  91. Kehoe, 2007, Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer's disease?, Lancet Neurol., 6, 373, 10.1016/S1474-4422(07)70077-7 · DOI · Paper page

Cited by

See all 165

Metadata

Authors
Kehoe, P. G., Miners, S., & Love, S.
Venue
Trends in Neurosciences
Publisher
Elsevier BV
Published
2009-12
Volume
32
Issue
12
Pages
619-628
ISSN
0166-2236 (ISSN-L)
DOI
10.1016/j.tins.2009.07.006
OpenAlex
W1981132320
Cited by
165
References
16
FWCI
2.48
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Angiotensins in Alzheimer's disease – friend or foe? https://app.cochat.ai/papers/10.1016/j.tins.2009.07.006
The paper
Kehoe, P. G., Miners, S., & Love, S. (2009). Angiotensins in Alzheimer's disease – friend or foe? Trends in Neurosciences. https://doi.org/10.1016/j.tins.2009.07.006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.